Recursion Pharmaceuticals Acquires Full Rights to REV102, Potential Oral Therapy for Rare Bone Disorder Hypophosphatasia
Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best small cap AI stocks to buy according to analysts.
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | ADAR1 Capital Management Daniel Schneeberger | 926,352 | $14,821,632 | +4412% | 0.68% |
| 2. | Citadel Investment Group Ken Griffin | 7,705,787 | $12,732,490 | +38650% | 0% |
| 3. | Viking Global Andreas Halvorsen | 524,347 | $8,389,552 | 0.02% | |
| 4. | Renaissance Technologies Jim Simons | 199,907 | $3,198,512 | +28% | 0% |
| 5. | Nantahala Capital Management Wilmot B. Harkey And Daniel Mack | 188,422 | $3,014,752 | -38% | 0.09% |
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $13.80 | 200 | $2,760.00 | 926,352 | 2026-05-19 | Filing | |
| $13.98 | 10,000 | $139,822.00 | 926,152 | 2026-05-19 | Filing | |
| $13.98 | 6,009 | $83,981.18 | 916,152 | 2026-05-18 | Filing | |
| $13.95 | 200 | $2,790.00 | 910,143 | 2026-05-15 | Filing | |
| $13.80 | 100 | $1,380.00 | 909,943 | 2026-05-15 | Filing |
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.06 | 789 | $3,992.34 | 4,115 | 2026-02-23 | Filing | |
| $8.20 | 100,000 | $820,000.00 | 2,378,969 | 2023-03-07 | Filing | |
| $8.20 | 100,000 | $820,000.00 | 2,378,969 | 2023-03-07 | Filing | |
| $12.50 | 50,329 | $629,112.50 | 1,251,755 | 2022-06-03 | Filing | |
| $12.50 | 99,671 | $1,245,887.50 | 2,478,969 | 2022-06-03 | Filing |
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 794,720 | $12,715,520 | 0% | |
| 2. | 378,551 | $6,056,816 | 0.12% | |
| 3. | 300,579 | $4,809,264 | 1.56% | |
| 4. | 172,497 | $2,759,952 | 0% | |
| 5. | 50,566 | $809,056 | 0% |